# US 10,030,250 B2 · Edible vaccines expressed in soybeans

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,030,250 B2
- Document ID: US10030250B2
- Status: Granted
- Kind: B2
- Application number: 12/692,722
- Filed: 2010-01-25
- Published: 2011-06-09
- Granted: 2018-07-24
- Earliest claimed: 2004-10-12
- Applicants: Kenneth John Piller; Kenneth Lee Bost
- Inventors: Kenneth John Piller; Kenneth Lee Bost
- Web page: https://patentgrep.com/patent/US10030250B2

## CPC

- C12N 15/8258: {for the production of oral vaccines (antigens) or immunoglobulins}
- A61K 39/0005: {Vertebrate antigens (from snakes A61K39/38)}
- A61K 39/02: Bacterial antigens
- A61K 39/0258: {Escherichia}
- A61K 39/35: Allergens
- A61P 31/04: Antibacterial agents
- A61P 31/14: for RNA viruses
- A61P 31/18: for HIV
- A61P 31/22: for herpes viruses
- A61K 2039/517: {Plant cells}
- A61K 2039/55544: {Bacterial toxins}
- C12N 2710/00088: for redistribution
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to vaccines that are made in transgenic soybeans for use in humans, animals of agricultural importance, pets, and wildlife. These vaccines are used as vaccines against viral, bacterial, fungal, parasitic or prion related diseases, cancer antigens, toxins, and autologous or self proteins. The transgenic soybeans of the instant invention also can be used for inducing tolerance to allergens or tolerance to autoimmune antigens, wherein an individual shows hypersensitivity to said allergen or has developed autoimmunity to autologous or self proteins, respectively. The invention also relates to prophylatically treating individuals and/or populations prior to showing hypersensitivity to allergens. Other aspects of the invention include using the transgenic soybeans as an oral contraceptive, and the expression of protein adjuvants in transgenic soybeans.

## Claims

### Claim 1

A soy formulation that induces mucosal and/or systemic tolerance, wherein the soy formulation is functional in an animal model when administered orally, wherein said soy formulation comprises a heterologous protein expressed from an exogenous gene, wherein said exogenous gene codes for a protein selected from the group consisting of acetylcholine receptor, Myelin Basic Protein, and Collagen Type II, and wherein said gene further comprises a sequence that encodes a polypeptide that acts as a targeting domain for epithelial cells, and wherein the exogenous gene is driven by a soybean beta-conglycinin 7S seed specific promoter and comprises a tobacco etch virus translational enhancer element.

### Claim 2 (depends on 1)

The soy formulation of claim 1, wherein said soy formulation derives from transgenic soybeans produced by transforming soybeans using a selectable marker that is the bar gene encoding resistance to the herbicide bialophos or the EPSPS gene encoding resistance to glyphosate.

### Claim 3 (depends on 1)

The soy formulation of claim 1, wherein the exogenous gene that codes for a protein is Myelin Basic Protein or acetylcholine receptor.

### Claim 4 (depends on 3)

The soy formulation of claim 3, wherein said soy formulation results from a transformed soybean that is selected using a selectable marker that is the bar gene encoding resistance to the herbicide bialophos or the EPSPS gene encoding resistance to glyphosate.

### Claim 5 (depends on 3)

The soy formulation of claim 3, wherein said soy formulation results from a transformed soybean that is selected using a selectable marker that is the bar gene encoding resistance to the herbicide bialophos.

### Claim 6 (depends on 3)

The soy formulation of claim 3, wherein said soy formulation results from a transformed soybean that is selected using a selectable marker that is the EPSPS gene encoding resistance to glyphosate.

### Claim 7 (depends on 1)

The soy formulation of claim 1, wherein the soy formulation is present in soy milk or soy powder.

### Claim 8 (depends on 7)

The soy formulation of claim 7, wherein the soy formulation is present in soy milk.

### Claim 9 (depends on 7)

The soy formulation of claim 7, wherein the soy formulation is present in soy powder.

### Claim 10 (depends on 2)

The soy formulation of claim 2, wherein the soy formulation is present in soy milk or soy powder.

### Claim 11 (depends on 3)

The soy formulation of claim 3, wherein the soy formulation is present in soy milk or soy powder.

### Claim 12 (depends on 4)

The soy formulation of claim 4, wherein the soy formulation is present in soy milk or soy powder.

### Claim 13 (depends on 12)

The soy formulation of claim 12, wherein the exogenous ene further comprises a terminator sequence that expresses a CaMV 35S polyadenylation sequence or a nopaline synthase polyadenylation sequence.

### Claim 14 (depends on 5)

The soy formulation of claim 5, wherein the soy formulation is present in soy milk or soy powder.

### Claim 15 (depends on 14)

The soy formulation of claim 14, wherein the soy formulation is present in soy milk.

### Claim 16 (depends on 14)

The soy formulation of claim 14, wherein the soy formulation is present in soy powder.

### Claim 17 (depends on 6)

The soy formulation of claim 6, wherein the soy formulation is present in soy milk or soy powder.

### Claim 18 (depends on 17)

The soy formulation of claim 17, wherein the soy formulation is present in soy powder.

### Claim 19 (depends on 17)

The soy formulation of claim 17, wherein the soy formulation is present in soy milk.
